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Abstract 
Background: Low sunshine exposure might contribute to IBD pathogenesis.  
Aim: To assess the geographic distribution of IBD incidence in relation to sunshine exposure in 
France, in order to test the hypothesis that higher sun exposure is associated with lower IBD risk.  
Methods: Using the national health insurance databases, incidence rates of CD and UC were 
estimated for each of 94 French administrative areas (“départements”), in 2000-2002. The surface 
UV radiation intensity was obtained by combining modeling and satellite data from Meteosat®, the 
European meteorological satellite. Relationships between incidence rates and sun exposure were 
tested for significance by using a Poisson regression. We mapped smoothed relative risks (sRR) for 
CD and UC, using a Bayesian approach and adjusting for sun exposure, in order to search for 
geographical variations.  
Results: Areas with a smoothed RR of CD incidence significantly above 1 corresponded to areas 
with low sunshine exposure, whereas those with high or medium sunlight exposure had smoothed 
RRs either lower than 1 or not significantly different from 1. There was no association between sun 
exposure and UC incidence.  
Conclusions: This geographic study suggests that low sunlight exposure is associated with an 
increased incidence of CD. Further studies are needed to determine if this association is causal.  
 
Key words: Crohn’s disease; ulcerative colitis; geographical variation; France; sun exposure.  
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INTRODUCTION 
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders of the 
gastrointestinal tract. Genetic predisposition of inflammatory bowel disease (IBD) is established, 
particularly in CD, in which several susceptibility genes that affect bacterial clearance (including 
autophagy), the IL23 pathway, and T cell homeostasis have been identified1. Environmental factors 
also contribute to IBD pathogenesis2. Smoking, appendectomy and intestinal infections have been 
reproducibly linked with susceptibility to IBD2. It is likely that other environmental factors increase 
IBD risk2. These environmental factors could possibly be found through the association between 
IBD and other diseases for which environmental factors are already known. 
An association between multiple sclerosis (MS) and IBD has been reproducibly reported and could 
occur more often than by chance alone3-4. Geographical, case-control and prospective studies have 
suggested that sun exposure may protect from MS5-8. Therefore, we hypothesized that the 
association between MS and IBD is due to shared environmental factors, especially sun exposure, 
and thus we assessed the geographic distribution of CD and UC in relation to sunshine exposure.   
 
MATERIALS AND METHODS 
Setting 
This study was conducted in metropolitan France (excluding Corsica and the overseas French 
territories) totalling 59,368,981 inhabitants on January 1, 2003. Its surface area is 535 280 km², with 
an average of 111 people per square kilometre. There are considerable variations, however, as half 
the population lives on just over 10% of the territory, and large areas remain sparsely populated.  
Geographical units 
This study was performed at the scale of “départements”, i.e. the 94 administrative areas 
(subsequently called departments), as described previously9.  
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IBD Data  
In France, patients with IBD, whatever their place of residence, are fully reimbursed for their health 
care expenses by the national health insurance (NHI) system. The IBD data used for this study were 
obtained from the French statutory NHI system, which is based on professional status. Three main 
subsystems included in the NHI, cover 96% of the French population. The general fund insures 
salaried workers and their families in private secondary and tertiary industries and in the public 
sector (i.e. 84% of the population). The agricultural fund insures farmers and agricultural employees 
and their families (i.e. 7% of the population). The third fund provides medical coverage to self-
employed professionals and their families (i.e. 5% of the population). Unemployed and retired 
people remain affiliated to the last subsystem they were affiliated to when employed.  
CD and UC are two of the 30 specified long-term illnesses which provide patients with a 100% 
reimbursement rate, thus covering the total cost of requested health care. Thus, all French IBD 
patients have equal access to free medical care. This full coverage by statutory health insurance is 
subject to prior NHI approval, after examination of an official form that certifies that the patient has 
CD or UC and that has been signed by the patient’s physicians (general practitioner and/or 
gastroenterologist). Each health insurance fund records individual data on an annual basis for all 
patients who have obtained 100 percent coverage for each of the 30 specified long-term illnesses. 
We contacted doctors in charge of national patient data files in the three insurance funds to request 
anonymous information concerning all new beneficiaries of 100 percent coverage for IBD granted 
between January 1, 2000 and December 31, 2002. We obtained centralized files covering the whole 
French territory. They contained the following individual information: age, sex, postcode of the 
place of residence, diagnosis that conferred the 100 percent coverage, coded either CD (ICD code 
K50) or UC (ICD code K51) with the tenth revision of the International Classification of Diseases 
(ICD). This study was approved by the “Commission Nationale de l’Informatique et des Libertés” 
(CNIL, Paris, France), a national commission which provides legal protection of computerized 
personal data. 
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Sun exposure data 
Ground radiometers are the most accurate method to measure sun exposure, but they are too few in 
number to offer a comprehensive geographical coverage. The surface UV radiation intensity can be 
obtained by combining modeling and satellite data from Meteosat®, the European meteorological 
satellite. This method provides a comprehensive map of sunlight exposure with a precision of 5 km. 
Correlation between measured and modelled erythemal daily doses was found to be highly 
significant10.  
Statistical analysis 
Incidence rates 
The analysis was conducted separately for CD and UC. IBD patients were tabulated by sex, 5-year 
age classes and administrative area. The number of insured people in each area on January 1, 2003 
was obtained from the health insurance funds and totalled to obtain the overall number of people 
affiliated with these funds within each area. For the population as a whole, incidence rates were 
calculated by sex for CD and UC, based on the number of all new beneficiaries of 100 percent 
coverage for CD or UC granted during the study period, with the person-years denominator being 
the sum of the insured population estimates for the 3 years in the three subsystems described above.  
Influence of sun exposure on incidence rates 
Ground UV dose from sunshine was expressed in kJ/m² and was provided by month and by 
administrative area for the years 1984 to 2002. We calculated a mean annual UV dose for the 
studied period, which was classified into quintiles, and linked with incidence data tabulated by area. 
Age- and sex- adjusted incidence rate ratios (IRR), with their 95% confidence intervals (CI), were 
estimated using the Poisson regression, for CD and UC. We used the likelihood ratio statistics to 
calculate P-values for each variable.  
Spatial analysis and disease mapping 
A spatial analysis with a Bayesian approach was then performed, as described previously9. Sun 
exposure was introduced as a covariate into this model and tested for improvement of the model fit, 
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which was adjusted for age and sex. The model provides smoothed Relative Ratios (RR) which are 
more accurate and steady than the traditional standardized incidence ratios.   
We mapped the 94 administrative areas grouped into 3 classes according to the value and 
significance of smoothed RR: administrative areas with smoothed RRs significantly lower than 1, 
administrative areas with smoothed RRs not significantly different from 1, and administrative areas  
with smoothed RRs significantly higher than 1. 
 
RESULTS 
From January 1, 2000 to December 31, 2002, 14,113 new patients with CD (including 8,138 
women and 5,975 men) and 12,339 new patients with UC (including 5,959 women and 6,380 men) 
were registered by the three health insurance funds, among the overall French insured population of 
57,098,525.  
The map of France showing the average annual erythemal daily dose (kJ/m²) by administrative area 
is displayed in figure 1.  
Crohn’s disease 
In the population as a whole, the incidence rate was 8.2 for 100,000 inhabitants (95% CI: 8.1-8.4) 
for the whole population, 7.1 (95% CI: 6.9-7.2) for men, and 9.4 (95% CI: 9.2-9.6) for women with 
no important variation between the three studied years. Table 1 shows the age and sex adjusted 
incidence rate ratios and 95% confidence intervals derived from the Poisson regression analysis for 
CD, according to quintiles of sun exposure, and taking as the reference the quintile of highest sun 
exposure. The two quintiles with the lowest sun exposure were associated with an increased IRR of 
CD. The intermediate quintile had an IRR not significantly different from 1. The second quintile 
with the highest sun exposure was associated with a decreased IRR of CD.  
Local UV dose improved the Bayesian model of geographic distribution of CD, and the effect of 
local UV dose was stronger than the effect of local spatial autocorrelation. Variations of smoothed 
RR of CD in both sexes according to sunlight exposure are displayed in Figure 2. Areas with a 
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smoothed RR significantly higher than 1 corresponded to areas with low sunlight exposure (North 
of France), whereas those with high or medium sunlight exposure had smoothed RRs either lowers 
than 1 (centre of France) or not significantly different from 1 (figure 2).  
Ulcerative colitis 
In the population as a whole, the incidence rate was 7.2 for 100,000 inhabitants (95% CI: 7.1-7.3), it 
was 7.7 (95% CI: 7.5-7.9) in men and 6.8 (95% CI: 6.6-7.0) in women. Table 2 shows the age and 
sex adjusted incidence rate ratios and 95% confidence intervals derived from the Poisson regression 
analysis for UC, according to quintiles of sun exposure. There was no statistically significant 
association between sun exposure and UC incidence (cf. Support Information). 
 
DISCUSSION 
The present study assessed the geographic distribution of IBD in relation to sun exposure. It appears 
that CD incidence is higher in geographical areas with a low sunshine exposure than in areas with 
high or medium sunshine exposure, where CD incidence is either lower than or not significantly 
different from the mean national incidence rate. Thus, there seems to be a threshold of sun exposure 
under which CD incidence increases. By contrast, no association between UC incidence and sun 
exposure was found.  
Our study is based on data derived from administrative health care records and relies on ecological 
data. These limitations have already been discussed in our previous papers9, 11. Moreover, in a 
recent paper concerning geographic mapping of IBD, Green and Bernstein suggest to use small 
geographic areas in order to minimize the misclassification of populations by risk categories12. 
However, the sun exposure data are available at the scale of “departments” and not at a smaller 
scale.  Additionally, the association between sun exposure and CD is not necessarily causal. It can 
be due to an underlying genetic or environmental factor which has a geographical distribution 
similar to that of sun exposure, such as chemicals, water or soil microbial ecology and diet. In a 
recent prospective study, high total protein intake, specifically animal protein, was associated with a 
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significantly increased risk of IBD in middle-aged French women13. It could be questioned whether 
this could confound the geographical variation of CD. However, the findings for protein intake 
were similar for CD and UC, unlike the present association between CD and sun exposure. If a role 
of vitamin D is suspected, the role of dietary vitamin D could also be questioned. It must be 
emphasized that in France, very few dairy products are fortified with vitamin D and about 90% of 
vitamin D is related to sun exposure. Thus a potential opposite effect of specific foods such as 
dairies through proteins on one hand and vitamin D on the other is most likely very limited.  
On the other hand, the association between CD and sun exposure could also be causal, as suggested 
by several epidemiological and biological data. Firstly, there is a reproducible North-South gradient 
of CD incidence which has been found in the USA, Scotland and France9, 14, 15. Sun exposure might 
well explain the North-South gradient found in these countries. Secondly, the geographic 
distribution of multiple sclerosis (MS) appears to be similar to that of CD in France and several 
lines of evidence suggest that sun exposure protects from MS16. A strong inverse correlation 
between UV radiation and MS prevalence has been found in a geographical study performed in 
Australia5. A case-control study has shown that exposure to the sun in infancy may protect against 
multiple sclerosis6. It has also been shown that people with the highest blood levels of vitamin D 
had the lowest risks of MS7. Furthermore, results from a cohort study of 187,500 nurses showed 
that women who consumed at least the current daily recommended dose of vitamin D have a lower 
risk of developing MS8. Exposure to the sun may explain the French North-South gradient of MS 
and CD. Thirdly, there is a biological plausibility for our findings17. Sun and vitamin D have been 
found to act as immune regulators. UV radiation and vitamin D have been shown to induce 
regulatory T cell function18. UV radiation induces immune suppression via induction of IL-4 and 
IL-10 and suppression of IL-12 production19. 1,25-dihydroxyvitamin D inhibits dendritic cell 
differentiation and maturation, which induces a shift in T cell differentiation from Th1 and Th17 to 
a Th2 phenotype20. Recent studies have found that vitamin D is also a key regulatory factor of 
innate immunity. Vitamin D, produced in response to UV radiation, stimulates the production of 
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cathelicidin, which can kill various viruses and bacteria, including the mycobacteria21. More 
recently, a study performed in primary cultures and lines of human monocytic and epithelial 
intestinal cells has found that 1,25-dihydroxyvitamin D stimulates the expression of NOD2 in the 
presence of its agonist muramyl dipeptide22. Taken together, these results suggest that low sunshine 
exposure and vitamin D deficiency impair innate immunity and induce a shift in T cell 
differentiation towards TH1/TH17 phenotype, which are both characteristic of CD.     
Our study suggests that low sunlight exposure is associated with higher CD risk. This potential 
association should be further investigated within case-control and cohort studies. If a protective role 
of sun exposure on CD risk is confirmed, prevention of CD through vitamin D supplementation 
should be tested in high-risk subjects. Vitamin D supplementation may also reduce the risk of 
relapse in patients with CD, as shown by a recent randomized trial23. 
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TABLES 
 
Table 1: Age- and sex-adjusted incidence rate ratios (IRR) and 95% confidence intervals (CI) 
derived from Poisson regression analysis for Crohn’s Disease according to the average annually 
erythemal daily dose  
 
 
Crohn’s disease 
 IRR 95% CI p-value 
Sex 
Female 
Male 
 
Reference 
0.76 
 
 
0.70 – 0.81 
<10-4 
Age (years) 
15 – 29 
0 – 14 
30 – 44  
45 – 59 
≥ 60 
 
Reference 
0.09 
0.70 
0.41 
0.26 
 
 
0.07 – 0.11 
0.64 – 0.76 
0.37 – 0.45 
0.23 – 0.29 
<10-4 
Average annually erythemal daily dose (kJ/m²) 
1.729 – 1.928 
1.606 – 1.725 
1.488 – 1.585 
1.397 – 1.484 
1.272 – 1.396 
 
Reference 
0.85 
0.90 
1.12 
1.42 
 
 
0.74 – 0.98 
0.78 – 1.04 
1.00 – 1.26 
1.27 – 1.58 
<10-4 
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Table 2: Age- and sex-adjusted incidence rate ratios (IRR) and 95% confidence intervals (CI) 
derived from Poisson regression analysis for Ulcerative Colitis according to the average annually 
erythemal daily dose  
 
Ulcerative colitis 
 IRR 95% CI  p-value 
Sex 
Female 
Male 
 
Reference 
1.13 
 
 
1.03 – 1.25 
0.01 
Age (years) 
25 – 49 
0 – 24 
50 – 74  
≥ 75 
 
Reference 
0.26 
0.69 
0.46 
 
 
0.22 – 0.30 
0.62 – 0.77 
0.37 – 0.57 
< 10-4 
Average erythemal daily dose (kJ/m²) 
1.729 – 1.928 
1.606 – 1.725 
1.488 – 1.585 
1.397 – 1.484 
1.272 – 1.396 
 
Reference 
0.86 
0.85 
0.87 
0.93 
 
 
0.73 – 1.01 
0.71 – 1.01 
0.75 – 1.01 
0.81 – 1.07 
0.25 
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FIGURES 
 
Figure 1: Map of France showing the average annually erythemal daily dose (kJ/m²) according to 
“departments”. 
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16 
 
Figure 2: Map of France showing age and sex adjusted CD smoothed Relative Risk (RR) obtained 
with the Bayesian model, taking into account the average annually erythemal daily dose  
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1 
Supporting information: Map of France showing age and sex adjusted UC smoothed Relative Risk 
(RR) obtained with the Bayesian model, taking into account the average annually erythemal daily 
dose  
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